Related references
Note: Only part of the references are listed.Morusin induces paraptosis-like cell death through mitochondrial calcium overload and dysfunction in epithelial ovarian cancer
Jing Xue et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2018)
Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma
Muthu K. Shanmugam et al.
FRONTIERS IN PHARMACOLOGY (2018)
YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction
Chun-Hua Dai et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
Regulation of selective autophagy: the p62/SQSTM1 paradigm
Trond Lamark et al.
SIGNALLING MECHANISMS IN AUTOPHAGY (2017)
Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells
He-Guo Jiang et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2017)
Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation
Toshimitsu Yamaoka et al.
MOLECULAR CANCER RESEARCH (2017)
Natural Compounds As Modulators of Non-apoptotic Cell Death in Cancer Cells
Luis Miguel Guaman-Ortiz et al.
CURRENT GENOMICS (2017)
EGFR gene deregulation mechanisms in lung adenocarcinoma: A molecular review
Evangelos Tsiambas et al.
PATHOLOGY RESEARCH AND PRACTICE (2016)
Withaferin A Induces ROS-Mediated Paraptosis in Human Breast Cancer Cell-Lines MCF-7 and MDA-MB-231
Kamalini Ghosh et al.
PLOS ONE (2016)
Non-canonical programmed cell death mechanisms triggered by natural compounds
Marc Diederich et al.
SEMINARS IN CANCER BIOLOGY (2016)
Co-inhibition of pol θ and HR genes efficiently synergize with cisplatin to suppress cisplatin-resistant lung cancer cells survival
Chun-Hua Dai et al.
ONCOTARGET (2016)
Cytoplasmic vacuolization in cell death and survival
Andrey V. Shubin et al.
ONCOTARGET (2016)
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
Shang-Gin Wu et al.
ONCOTARGET (2016)
Mechanisms of resistance to EGFR-targeted drugs: lung cancer
Floriana Morgillo et al.
ESMO OPEN (2016)
Bafilomycin A1 disrupts autophagic flux by inhibiting both V-ATPase-dependent acidification and Ca-P60A/SERCA-dependent autophagosome-lysosome fusion
Caroline Mauvezin et al.
AUTOPHAGY (2015)
ClpX stimulates the mitochondrial unfolded protein response (UPRmt) in mammalian cells
Natalie Al-Furoukh et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2015)
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
Yoshihisa Kobayashi et al.
CLINICAL CANCER RESEARCH (2015)
The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression
Siyuan Dong et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin
Matthew G. Oser et al.
LANCET ONCOLOGY (2015)
Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI
Samuel J. Klempner et al.
LUNG CANCER (2015)
Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A
Ting-Ting Chao et al.
ONCOTARGET (2015)
RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells
Chun-Hua Dai et al.
JOURNAL OF BIOMEDICAL SCIENCE (2015)
Endoplasmic Reticulum Stress in Malignancy
Hanna J. Clarke et al.
CANCER CELL (2014)
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2014)
Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives
Xinghua Cheng et al.
ONCOTARGETS AND THERAPY (2014)
Stronger proteasomal inhibition and higher CHOP induction are responsible for more effective induction of paraptosis by dimethoxycurcumin than curcumin
M. J. Yoon et al.
CELL DEATH & DISEASE (2014)
NBR1 acts as an autophagy receptor for peroxisomes
Elizabeth Deosaran et al.
JOURNAL OF CELL SCIENCE (2013)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistant Disease
Kadoaki Ohashi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
Marina Chiara Garassino et al.
LANCET ONCOLOGY (2013)
Manumycin A inhibits triple-negative breast cancer growth through LC3-mediated cytoplasmic vacuolation death
P. K. Singha et al.
CELL DEATH & DISEASE (2013)
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
Gang Chen et al.
BMC MEDICINE (2012)
Simultaneous mitochondrial Ca2+ overload and proteasomal inhibition are responsible for the induction of paraptosis in malignant breast cancer cells
Mi Jin Yoon et al.
CANCER LETTERS (2012)
Paraptosis accompanied by autophagy and apoptosis was induced by celastrol, a natural compound with influence on proteasome, ER stress and Hsp90
Wen-Bo Wang et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2012)
Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort
Seiji Yano et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer
Masayuki Takeda et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Characteristics and possible functions of mitochondrial Ca2+ transport mechanisms
Thomas E. Gunter et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS (2009)
CELASTROL POTENTIATES RADIOTHERAPY BY IMPAIRMENT OF DNA DAMAGE PROCESSING IN HUMAN PROSTATE CANCER
Yao Dai et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
A novel role for MAP1 LC3 in nonautophagic cytoplasmic vacuolation death of cancer cells
R. Kar et al.
ONCOGENE (2009)
Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3
Shunsuke Kimura et al.
AUTOPHAGY (2007)
Coordinate regulation of phospholipid biosynthesis and secretory pathway gene expression in XBP-1 (S)-induced endoplasmic reticulum biogenesis
Rungtawan Sriburi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Herbal medications commonly used in the practice of rheumatology: Mechanisms of action, efficacy, and side effects
AR Setty et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2005)
Cell death independent of caspases:: A review
LE Bröker et al.
CLINICAL CANCER RESEARCH (2005)
XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation
AL Shaffer et al.
IMMUNITY (2004)
Triggering caspase-independent cell death to combat cancer
IS Mathiasen et al.
TRENDS IN MOLECULAR MEDICINE (2002)
Share Paper
